This is what analysts have to say about Hill-Rom Holdings, Inc. (NYSE:HRC) after last week.

Hill-Rom Holdings, Inc. (NYSE:HRC) Logo
Investors sentiment decreased to 1.08 in Q3 2018. Its down 0.12, from 1.2 in 2018Q2. It is negative, as 19 investors sold Hill-Rom Holdings, Inc. shares while 99 reduced holdings. 40 funds opened positions while 88 raised stakes. 53.66 million shares or 1.60% less from 54.53 million shares in 2018Q2 were reported.
Creative Planning reported 0.01% stake. Credit Suisse Ag stated it has 0.01% of its portfolio in Hill-Rom Holdings, Inc. (NYSE:HRC). Tower Capital Ltd Limited Liability Company (Trc) accumulated 0.04% or 6,133 shares. Cwm Ltd reported 52 shares. Moreover, South Dakota Invest Council has 0.02% invested in Hill-Rom Holdings, Inc. (NYSE:HRC) for 8,300 shares. 66,473 were accumulated by Strs Ohio. Amer Century Cos holds 355,682 shares or 0.03% of its portfolio. Etrade Cap Mgmt Ltd Liability Co owns 8,883 shares for 0.02% of their portfolio. Huntington Bankshares, Ohio-based fund reported 3,110 shares. Southernsun Asset Management Lc holds 1.93% of its portfolio in Hill-Rom Holdings, Inc. (NYSE:HRC) for 447,256 shares. Shell Asset Management Co invested in 14,341 shares or 0.03% of the stock. Verition Fund Management Ltd Liability Corp stated it has 0.02% in Hill-Rom Holdings, Inc. (NYSE:HRC). Argi Inv Services Limited Co invested in 0.01% or 2,296 shares. Blackrock has invested 0.03% in Hill-Rom Holdings, Inc. (NYSE:HRC). Wellington Mngmt Grp Llp holds 4.53 million shares.

Since November 28, 2018, it had 0 buys, and 1 sale for $713,769 activity.

Hill-Rom Holdings, Inc. (NYSE:HRC) Ratings Coverage

Among 5 analysts covering Hill-Rom Holdings (NYSE:HRC), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Hill-Rom Holdings had 7 analyst reports since July 17, 2018 according to SRatingsIntel. On Wednesday, January 2 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The firm earned “Overweight” rating on Tuesday, July 17 by KeyBanc Capital Markets. Raymond James maintained it with “Outperform” rating and $100 target in Monday, July 30 report. The rating was maintained by Morgan Stanley with “Equal-Weight” on Thursday, October 11. Raymond James maintained Hill-Rom Holdings, Inc. (NYSE:HRC) rating on Monday, November 5. Raymond James has “Outperform” rating and $105 target. Below is a list of Hill-Rom Holdings, Inc. (NYSE:HRC) latest ratings and price target changes.

02/01/2019 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $100 New Target: $98 Maintain
28/11/2018 Broker: UBS Rating: Buy New Target: $115 Initiates Coverage On
05/11/2018 Broker: Raymond James Old Rating: Outperform New Rating: Outperform Old Target: $100 New Target: $105 Maintain
16/10/2018 Broker: Barclays Capital Rating: Equal-Weight New Target: $95 Initiates Coverage On
11/10/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $95 New Target: $100 Maintain
30/07/2018 Broker: Raymond James Old Rating: Outperform New Rating: Outperform Old Target: $97 New Target: $100 Maintain
17/07/2018 Broker: KeyBanc Capital Markets Old Rating: Overweight New Rating: Overweight Old Target: $97 New Target: $115 Maintain

The stock decreased 0.26% or $0.24 during the last trading session, reaching $92.65. About 176,117 shares traded. Hill-Rom Holdings, Inc. (NYSE:HRC) has risen 12.45% since January 14, 2018 and is uptrending. It has outperformed by 12.45% the S&P500.

Hill-Rom Holdings, Inc. operates as a medical technology firm worldwide. The company has market cap of $6.23 billion. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, communications technologies and software solutions, and health care furniture; and medical equipment management services, as well as sells equipment service contracts for its capital equipment. It has a 24.84 P/E ratio. The firm also offers patient monitoring and diagnostics products, such as blood pressure, physical assessment, vital signs monitoring, diagnostic cardiopulmonary, diabetic retinopathy screening, and thermometry products; and respiratory health products, including Vest, VitalCough, and MetaNeb systems to assist patients in the mobilization of retained blockages.

Hill-Rom Holdings, Inc. (NYSE:HRC) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.